OMNIVERSE: A Phase 1b/2 Study of Oral Azacitidine Plus Venetoclax in Patients with Relapsed/Refractory (R/R) or Newly Diagnosed (ND) Acute Myeloid Leukemia (AML)

被引：0
|
作者：
Ravandi, Farhad [1 ]
Carraway, Hetty E. [2 ]
Taningco, Lilia [3 ]
Dilley, Kimberley [3 ]
Laille, Eric [3 ]
Gong, Jing [3 ]
de Menezes, Daniel Lopes [3 ]
Wei, Andrew H. [4 ,5 ]
机构：
[1] Univ Texas M D Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
[2] Cleveland Clin, Taussig Canc Inst, Leukemia Program, Cleveland, OH USA
[3] Bristol Myers Squibb, Princeton, NJ USA
[4] Monash Univ, Melbourne, Australia
[5] Alfred Hosp, Melbourne, Australia
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-147293
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2314
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study
    Pollyea, Daniel A.
    Pratz, Keith
    Letai, Anthony
    Jonas, Brian A.
    Wei, Andrew H.
    Pullarkat, Vinod
    Konopleva, Marina
    Thirman, Michael J.
    Arellano, Martha
    Becker, Pamela S.
    Chyla, Brenda
    Hong, Wan-Jen
    Jiang, Qi
    Potluri, Jalaja
    DiNardo, Courtney D.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (02) : 208 - 217
  • [22] The propriety of upgrading responses to venetoclax plus azacitidine in newly diagnosed patients with acute myeloid leukemia
    Abbott, Diana
    Cherry, Evan
    Amaya, Maria
    McMahon, Christine
    Schwartz, Marc
    Winters, Amanda
    Schowinsky, Jeffrey
    Jordan, Craig T.
    Smith, Clayton
    Gutman, Jonathan A.
    Pollyea, Daniel A.
    [J]. LEUKEMIA & LYMPHOMA, 2021, 62 (06) : 1466 - 1473
  • [23] Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine ( AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients
    Gojo, Ivana
    Stuart, Robert K.
    Webster, Jonathan
    Blackford, Amanda
    Varela, Juan Carlos
    Morrow, Jillian
    DeZern, Amy E.
    Foster, Matthew C.
    Levis, Mark J.
    Coombs, Catherine C.
    Prince, Gabrielle T.
    Smith, B. Douglas
    Van Deventer, Hendrik W.
    Jamieson, Katarzyna
    Varadhan, Ravi
    Vincent, Benjamin G.
    Serody, Jonathan S.
    Luznik, Leo
    Zeidner, Joshua F.
    [J]. BLOOD, 2019, 134
  • [24] Promising Safety and Efficacy Results from an Ongoing Phase 1b Study of Pembrolizumab Combined with Decitabine in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
    Agrawal, Vaibhav
    Croslin, Cindy
    Beltran, Asuscena L.
    Zhang, Jianying
    Palmer, Joycelynne
    Quy Huynh-Tran
    Hernandez, Rochelle
    Thomas, Sandra
    Robbins, Marjorie
    Aribi, Ahmed
    Ali, Haris
    Stein, Anthony S.
    Budde, Elizabeth L.
    Al Malki, Monzr M.
    Marcucci, Guido
    [J]. BLOOD, 2022, 140 : 6235 - 6236
  • [25] A Systematic Review of Venetoclax and Azacitidine: Effectiveness and Safety for Newly Diagnosed and Relapsed Acute Myeloid Leukemia Patients
    Ibrahim, Ahmed
    Yousaf, Muhammad Abdullah
    Anwar, Zain
    Anum
    Batool, Maha
    Rehman, Mohammad
    Safdar, Omar A.
    Khattak, Zeeshan Ahmed
    Faraz, Fatima
    Khalid, Huma
    [J]. BLOOD, 2023, 142
  • [26] A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes
    Zeidan, Amer M.
    Borate, Uma
    Pollyea, Daniel A.
    Brunner, Andrew M.
    Roncolato, Fernando
    Garcia, Jacqueline S.
    Filshie, Robin
    Odenike, Olatoyosi
    Watson, Anne Marie
    Krishnadasan, Ravitharan
    Bajel, Ashish
    Naqvi, Kiran
    Zha, Jiuhong
    Cheng, Wei-Han
    Zhou, Ying
    Hoffman, David
    Harb, Jason G.
    Potluri, Jalaja
    Garcia-Manero, Guillermo
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (02) : 272 - 281
  • [27] A Phase IB/II Study of Lirilumab with Azacytidine in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
    Daver, Naval
    Boddu, Prajwal
    Ravandi, Farhad
    Jabbour, Elias
    Borthakur, Gautam
    DiNardo, Courtney
    Konopleva, Marina
    Pemmaraju, Naveen
    Kadia, Tapan
    Jain, Nitin
    Pierce, Sherry
    Hussain, Nawar
    Ning, Jing
    Nogueras-Gonzalez, Graciela
    Basu, Sreyashi
    Cortes, Jorge
    Sharma, Padmanee
    Kantarjian, Hagop
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (10): : S6 - S7
  • [28] A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia
    Saxena, Kapil
    Herbrich, Shelley M.
    Pemmaraju, Naveen
    Kadia, Tapan M.
    DiNardo, Courtney D.
    Borthakur, Gautam
    Pierce, Sherry A.
    Jabbour, Elias
    Wang, Sa A.
    Bueso-Ramos, Carlos
    Loghavi, Sanam
    Tang, Guillin
    Cheung, Cora M.
    Alexander, Lynette
    Kornblau, Steven
    Andreeff, Michael
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Konopleva, Marina Y.
    Daver, Naval
    [J]. CANCER, 2021, 127 (20) : 3761 - 3771
  • [29] Dose escalation results of a phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in patients (Pts) with relapsed/refractory (r/r) acute myeloid leukemia (AML)
    Erba, Harry Paul
    Becker, Pamela S.
    Shami, Paul J.
    Grunwald, Michael Richard
    Flesher, Donna L.
    Zhang, Yilong
    Rasmussen, Erik
    Henary, Haby A.
    Wang, Eunice S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [30] Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study
    Garcia-Manero, Guillermo
    Abaza, Yasmin
    Takahashi, Koichi
    Medeiros, Bruno C.
    Arellano, Martha
    Khaled, Samer K.
    Patnaik, Mrinal
    Odenike, Olatoyosi
    Sayar, Hamid
    Tummala, Mohan
    Patel, Prapti
    Maness-Harris, Lori
    Stuart, Robert
    Traer, Elie
    Karamlou, Kasra
    Yacoub, Abdulraheem
    Ghalie, Richard
    Giorgino, Ruben
    Atallah, Ehab
    [J]. BLOOD ADVANCES, 2019, 3 (04) : 508 - 518
12345